GlassScriptPhysician profile
Morgan R Brown
NPI 1194219105
$3,277.74
in general payments reported to CMS, 2019-2025
29 companies · $828 in 2025
The $828 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $365 · 2022: $726 · 2023: $779 · 2024: $580 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,186.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $680.73 | 2021-2025 | |
| Pfizer INC. | $522.48 | 2021-2025 | |
| Amgen INC. | $285.31 | 2021-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $153.99 | 2021-2025 | Farxiga, Brilinta, Wainua |
| E.R. Squibb & Sons, L.L.C. | $153.94 | 2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $118.41 | 2021-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.37 | 2022-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $112.13 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $106.72 | 2021-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $100.79 | 2021-2023 | |
| Abbott Laboratories | $99.17 | 2021-2023 | Cardiomems |
| Actelion Pharmaceuticals US, INC. | $96.62 | 2021-2024 | Opsumit, Uptravi |
| Vital Connect, INC | $87.17 | 2023-2024 | Vitalpatch Rtm |
| Boston Scientific Corporation | $84.62 | 2022-2024 | Ekosonic, Eluvia |
| Alnylam Pharmaceuticals INC. | $74.65 | 2023-2025 | Onpattro |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $72.24 | 2021-2024 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $60.40 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $57.14 | 2022-2025 | |
| Abiomed | $51.17 | 2024-2025 | Impella |
| Novo Nordisk INC | $42.25 | 2024 | Ozempic, Rybelsus |
| Pacira Pharmaceuticals Incorporated | $40.29 | 2024-2025 | Iovera, Exparel, Zilretta |
| Edwards Lifesciences Corporation | $27.51 | 2025 | Sapien 3 Ultra Resilia |
| Amarin Pharma, INC. | $26.98 | 2021 | |
| Genzyme Corporation | $18.93 | 2023 | |
| Chiesi USA, INC. | $18.88 | 2025 | Juxtapid |
| Kowa Pharmaceuticals America, INC. | $18.71 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $18.53 | 2024 | Arcalyst |
| Lilly USA, LLC | $15.90 | 2025 | Jardiance |
| Angiodynamics, INC. | $14.71 | 2024 | Auryon Laser System 100-120 Vac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.